Pharma Mar, S.A. (PHMMF)
USD 88.18
(-16.49%)
USD 88.18
(-16.49%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 147.78 Million EUR | -13.22% |
| 2022 | 170.3 Million EUR | -10.59% |
| 2021 | 190.46 Million EUR | -16.29% |
| 2020 | 227.53 Million EUR | 94.06% |
| 2019 | 117.24 Million EUR | -16.37% |
| 2018 | 140.2 Million EUR | -14.89% |
| 2017 | 164.73 Million EUR | -4.58% |
| 2016 | 172.64 Million EUR | 24.29% |
| 2015 | 138.9 Million EUR | -1.71% |
| 2014 | 141.32 Million EUR | 0.99% |
| 2013 | 139.93 Million EUR | -13.14% |
| 2012 | 161.1 Million EUR | -12.12% |
| 2011 | 183.31 Million EUR | -6.45% |
| 2010 | 195.96 Million EUR | 15.15% |
| 2009 | 170.17 Million EUR | 7.57% |
| 2008 | 158.19 Million EUR | 18.49% |
| 2007 | 133.51 Million EUR | 13.89% |
| 2006 | 117.23 Million EUR | 248.07% |
| 2005 | 33.68 Million EUR | -6.72% |
| 2004 | 36.1 Million EUR | -73.49% |
| 2003 | 136.19 Million EUR | 30.29% |
| 2002 | 104.53 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 150.95 Million EUR | 11.23% |
| 2024 Q1 | 141.22 Million EUR | -4.44% |
| 2024 Q2 | 135.72 Million EUR | -3.9% |
| 2023 Q4 | 147.78 Million EUR | 3.19% |
| 2023 Q2 | 148.38 Million EUR | -5.36% |
| 2023 Q3 | 143.21 Million EUR | -3.48% |
| 2023 Q1 | 156.78 Million EUR | -7.94% |
| 2023 FY | 147.78 Million EUR | -13.22% |
| 2022 Q3 | 166.59 Million EUR | -9.38% |
| 2022 Q4 | 170.3 Million EUR | 2.23% |
| 2022 FY | 170.3 Million EUR | -10.59% |
| 2022 Q1 | 176.22 Million EUR | -7.48% |
| 2022 Q2 | 183.83 Million EUR | 4.32% |
| 2021 Q4 | 190.46 Million EUR | -6.86% |
| 2021 FY | 190.46 Million EUR | -16.29% |
| 2021 Q2 | 207.68 Million EUR | -4.55% |
| 2021 Q1 | 217.57 Million EUR | -4.38% |
| 2021 Q3 | 204.48 Million EUR | -1.54% |
| 2020 Q3 | 231.58 Million EUR | -6.89% |
| 2020 Q2 | 248.72 Million EUR | 25.48% |
| 2020 Q1 | 198.22 Million EUR | 69.07% |
| 2020 FY | 227.53 Million EUR | 94.06% |
| 2020 Q4 | 227.53 Million EUR | -1.75% |
| 2019 Q1 | 158.6 Million EUR | 13.13% |
| 2019 Q3 | 121.74 Million EUR | -8.82% |
| 2019 Q4 | 117.24 Million EUR | -3.69% |
| 2019 FY | 117.24 Million EUR | -16.37% |
| 2019 Q2 | 133.51 Million EUR | -15.82% |
| 2018 Q1 | 164 Million EUR | -0.44% |
| 2018 Q4 | 140.2 Million EUR | -4.37% |
| 2018 Q3 | 146.61 Million EUR | -10.87% |
| 2018 FY | 140.2 Million EUR | -14.89% |
| 2018 Q2 | 164.48 Million EUR | 0.29% |
| 2017 Q1 | 170.54 Million EUR | -1.21% |
| 2017 FY | 164.73 Million EUR | -4.58% |
| 2017 Q3 | 167.48 Million EUR | -6.44% |
| 2017 Q2 | 179 Million EUR | 4.96% |
| 2017 Q4 | 164.73 Million EUR | -1.64% |
| 2016 Q4 | 172.64 Million EUR | 12.53% |
| 2016 Q3 | 153.41 Million EUR | -5.23% |
| 2016 FY | 172.64 Million EUR | 24.29% |
| 2016 Q2 | 161.88 Million EUR | 6.14% |
| 2016 Q1 | 152.52 Million EUR | 9.8% |
| 2015 FY | 138.9 Million EUR | -1.71% |
| 2015 Q4 | 138.9 Million EUR | -17.7% |
| 2015 Q1 | 139.64 Million EUR | -1.19% |
| 2015 Q2 | 150.58 Million EUR | 7.83% |
| 2015 Q3 | 168.77 Million EUR | 12.09% |
| 2014 Q3 | 147.78 Million EUR | -4.63% |
| 2014 Q4 | 141.32 Million EUR | -4.37% |
| 2014 Q2 | 154.94 Million EUR | 11.19% |
| 2014 Q1 | 139.35 Million EUR | -0.42% |
| 2014 FY | 141.32 Million EUR | 0.99% |
| 2013 FY | 139.93 Million EUR | -13.14% |
| 2013 Q1 | 161.94 Million EUR | 0.52% |
| 2013 Q2 | 154.48 Million EUR | -4.6% |
| 2013 Q3 | 149.21 Million EUR | -3.42% |
| 2013 Q4 | 139.93 Million EUR | -6.22% |
| 2012 Q3 | 177.53 Million EUR | -4.3% |
| 2012 Q1 | 183.33 Million EUR | 0.01% |
| 2012 FY | 161.1 Million EUR | -12.12% |
| 2012 Q2 | 185.5 Million EUR | 1.18% |
| 2012 Q4 | 161.1 Million EUR | -9.25% |
| 2011 Q4 | 183.31 Million EUR | -7.53% |
| 2011 FY | 183.31 Million EUR | -6.45% |
| 2011 Q3 | 198.24 Million EUR | -0.01% |
| 2011 Q1 | 189.82 Million EUR | -3.13% |
| 2011 Q2 | 198.27 Million EUR | 4.45% |
| 2010 Q4 | 195.96 Million EUR | -2.81% |
| 2010 Q1 | 175.5 Million EUR | 3.13% |
| 2010 Q3 | 201.62 Million EUR | -0.99% |
| 2010 Q2 | 203.63 Million EUR | 16.02% |
| 2010 FY | 195.96 Million EUR | 15.15% |
| 2009 Q2 | 182.05 Million EUR | 13.26% |
| 2009 Q4 | 170.17 Million EUR | -6.54% |
| 2009 FY | 170.17 Million EUR | 7.57% |
| 2009 Q3 | 182.08 Million EUR | 0.02% |
| 2009 Q1 | 160.73 Million EUR | 1.61% |
| 2008 Q4 | 158.19 Million EUR | 0.0% |
| 2008 FY | 158.19 Million EUR | 18.49% |
| 2007 FY | 133.51 Million EUR | 13.89% |
| 2006 FY | 117.23 Million EUR | 248.07% |
| 2005 FY | 33.68 Million EUR | -6.72% |
| 2004 FY | 36.1 Million EUR | -73.49% |
| 2003 FY | 136.19 Million EUR | 30.29% |
| 2002 FY | 104.53 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Evofem Biosciences, Inc. | 72.47 Million USD | -103.923% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -1461.232% |
| CSL Limited | 18.62 Billion USD | 99.206% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -150.423% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2607.867% |
| BioStem Technologies, Inc. | 15.9 Million USD | -829.193% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -194.018% |
| Qrons Inc. | 1.48 Million USD | -9827.031% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -18172.267% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -97.257% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -703.03% |
| Skye Bioscience, Inc. | 14.07 Million USD | -950.189% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -330544.8% |
| Rebus Holdings, Inc. | 5.24 Million USD | -2719.248% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -73382.468% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -538612.5% |
| Genscript Biotech Corporation | 1.32 Billion USD | 88.854% |
| Neon Bloom, Inc. | 1.22 Million USD | -11952.148% |
| Adynxx, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -177.244% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -1442.315% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -34956.029% |
| SQZ Biotechnologies Company | 50.03 Million USD | -195.34% |
| Intellipharmaceutics International Inc. | 12 Million USD | -1130.643% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -3737.152% |
| Mesoblast Limited | 188.44 Million USD | 21.576% |
| Marizyme, Inc. | 26.67 Million USD | -454.006% |
| Genus plc | 485 Million USD | 69.529% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -2429.43% |
| Pharming Group N.V. | 244.07 Million USD | 39.45% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -7252.012% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -5773.042% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -3789.079% |
| ContraFect Corporation | 32.53 Million USD | -354.29% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -7358.961% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -3760.987% |
| IMV Inc. | 37.93 Million USD | -289.597% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -1154.734% |
| MultiCell Technologies, Inc. | 1617.67 USD | -9135570.44% |
| ONE Bio Corp. | 27.49 Million USD | -437.482% |
| Accustem Sciences Inc. | 1.07 Million USD | -13593.445% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -90.895% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -6887.242% |
| Q BioMed Inc. | 8.13 Million USD | -1717.117% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -78.194% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -2771.823% |
| Biomind Labs Inc. | 1.49 Million USD | -9761.458% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -24.48% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -1534.393% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -10206.787% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -103904.363% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -2472.043% |
| GB Sciences, Inc. | 5.41 Million USD | -2627.89% |
| Alpha Cognition Inc. | 7.16 Million USD | -1962.661% |
| HST Global, Inc. | 593.59 Thousand USD | -24796.688% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -11636.485% |
| Halberd Corporation | 728.71 Thousand USD | -20180.108% |
| Enzolytics Inc. | 365.26 Million USD | 59.541% |
| Agentix Corp. | 2.51 Million USD | -5786.547% |
| Resverlogix Corp. | 67.39 Million USD | -119.279% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -17520.05% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 66.786% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -8522.229% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -497.207% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -1141.567% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -3932.152% |
| AVAX Technologies, Inc. | 3.99 Million USD | -3600.412% |
| Zenith Capital Corp. | 27.56 Thousand USD | -535954.989% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -61824.376% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -3857.496% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -21606.466% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -5350.021% |
| Kadimastem Ltd | 3.5 Million USD | -4116.565% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -220708.618% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -31702.306% |
| LadRx Corporation | 2.2 Million USD | -6615.888% |
| Cell Source, Inc. | 15.8 Million USD | -834.951% |
| Regen BioPharma, Inc. | 5.45 Million USD | -2607.867% |
| NovAccess Global Inc. | 7.86 Million USD | -1780.041% |
| Affymax, Inc. | 8.87 Million USD | -1565.934% |
| Itoco Inc. | 1.65 Million USD | -8839.595% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -7103.525% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -2343.131% |
| Mobile Lads Corp. | 1.31 Million USD | -11151.263% |
| CytoDyn Inc. | 127.89 Million USD | -15.553% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -353461.09% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -9334.83% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -1237.991% |
| SYBLEU INC | 681.41 Thousand USD | -21588.022% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -2321.949% |
| International Stem Cell Corporation | 5.27 Million USD | -2700.55% |
| Bioxytran, Inc. | 3.24 Million USD | -4447.93% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -23515.033% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -3100.801% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -260.486% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -563.755% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -7196.63% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -2597.791% |
| Neutra Corp. | 973.52 Thousand USD | -15080.339% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -409.34% |
| PureTech Health plc | 125.58 Million USD | -17.679% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -3833.46% |
| IXICO plc | 1.9 Million USD | -7676.963% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -619.884% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -43.031% |
| CSL Limited | 18.62 Billion USD | 99.206% |
| Cellectis S.A. | 249.36 Million USD | 40.737% |